Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment decisions, but its precise role in Philadelphia chromosome positive ALL is less clear. This uncertainty results largely from methodological differences relating to the use of real-time quantitative PCR (qRT-PCR) to measure BCR-ABL1 transcript levels for MRD analysis. We here describe the first results by the EURO-MRD consortium on standardization of qRT-PCR for the e1a2 BCR-ABL1 transcript in Ph + ALL, designed to overcome the lack of standardisation of laboratory procedures and data interpretation. Standardised use of EAC primer/probe sets and of centrally prepared plasmid standards had the greatest impact on reducing interlaboratory variability. In QC1 the proportion of analyses with BCR-ABL1/ABL1 ratios within half a log difference were 40/67 (60%) and 52/67 (78%) at 10 −3 and 36/67 (53%) and 53/67 (79%) at 10 −4 BCR-ABL1/ABL1. Standardized RNA extraction, cDNA synthesis and cycler platforms did not improve results further, whereas stringent application of technical criteria for assay quality and uniform criteria for data interpretation and reporting were essential. We provide detailed laboratory recommendations for the standardized MRD analysis in routine diagnostic settings and in multicenter clinical trials for Ph + ALL.
Introduction
Minimal residual disease (MRD) during treatment for acute lymphoblastic leukemia (ALL) is predictive of outcome and is an accepted measure of response in pediatric and adult ALL [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . The value of MRD for therapeutic decisions [6, 12] relies on the precision and reproducibility of MRD measurements. For Ph-negative ALL, these are typically based on DNA-based quantitative PCR (qPCR) analysis of immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements. This methodology has been optimized and standardised internationally as part of the BIOMED concerted action [13, 14] and subsequently the EuroMRD Consortium, formerly European Study Group on MRD detection in ALL (ESG-MRD-ALL) [14] [15] [16] [17] [18] .
For Ph + ALL, standard MRD monitoring of BCR-ABL1 by qRT-PCR has been suggested to provide better and earlier prediction of relapse than the Ig/TCR approach [19] . Advantages of reverse transcription real-time quantitative PCR (qRT-PCR) include high sensitivity, speed and low cost, without need for identification of patient-specific MRD markers. Major limitations are the diversity of qRT-PCR protocols, instability and variable expression levels of RNA, risk of cross-contamination and variability in data interpretation and reporting of results. Thus, clinical trials using comparable therapeutic regimens for Ph + ALL have reported widely varying rates and degrees of molecular response after induction and consolidation therapy [1, [20] [21] [22] [23] [24] [25] [26] . As precise and reproducible MRD measurements are critical to ensure comparability of results between trials and the validity of MRD-based treatment decisions, standardisation of qRT-PCR procedures, agreement on data interpretation and stringent quality control (QC) measures are essential [16, 18, [27] [28] [29] [30] .
Initial efforts to standardize qRT-PCR analysis were conducted within the Europe Against Cancer (EAC) program, which designed and validated EAC primer and probe sets for the most frequent leukemia-associated fusion genes [16, 29] . In contrast to the chronic myeloid leukemia (CML) community, which initiated international and still ongoing standardisation attempts in 2003 [31, 32] , no equivalent optimisation and standardisation has been conducted for Ph + ALL. The importance of high sensitivity and accuracy of quantitating MRD levels in this clinically aggressive disease [33] prompted us to comparatively evaluate the impact of methodological differences in qRT-PCR analysis of BCR-ABL1, to assess measures to improve the interlaboratory variability and reproducibility of e1a2 BCR-ABL1 detection, and to define guidelines for work-flow and reporting of e1a2 BCR-ABL1 transcript levels. This study focussed on the e1a2 breakpoint because of its predominance in Ph + ALL, as opposed to the e13a2 and e14a2 breakpoints characteristic of CML [34] . We here report the consensus recommendations of the EuroMRD Consortium for conducting and reporting MRD analyses in patients with Ph + ALL, which is based on the data generated during the first 10 QC rounds.
Organisation and definition of aims
European multinational cooperative study group trials EsPhALL [35] and EWALL-PH01 [24] for pediatric and adult Ph + ALL respectively, were the first to focus on accuracy and comparability of MRD results generated in the different national reference laboratories. Most of these laboratories participated in standardisation and quality control studies for immunoglobulin and T-cell receptor rearrangement-based MRD assessment within the EuroMRD Consortium. Positive experience with these studies led to analogous efforts for the RNA-based quantitation of BCR-ABL1. Several laboratories of the European Working Group for Adult ALL (EWALL) as well as those participating in BCR-ABL1 quantification in CML joined this consortium.
Successive aims and work programs were designed in biannual group meetings, in which results of the studies were discussed. 35 laboratories participated in the first 10 QC rounds, the results of which are provided in this paper. The coordinating centre in Frankfurt was responsible for central preparation and biannual shipment of samples, data collection and analysis.
Materials and Methods

Study design
Several successive phases of blinded testing were conducted, described for each QC round in supplemental table 1. Initially, centrally prepared samples were applied to RNA-extraction, cDNA-synthesis and qRT-PCR for BCR-ABL1 and ABL1 with the standard reagents and methods used by the participating laboratories by means of questionnaires. (Suppl. data)
A second phase systematically compared the effect of (i) RNA-extraction, (ii) cDNA synthesis, and (iii) qRT-PCR by applying routine procedures to centrally produced material. cDNA-synthesis and real-time PCR were occasionally repeated on separate days to enhance comparability of the individual experimental steps.
The third phase (QC10) tested the consistency of results and analytical procedures. QC7 was a detailed re-analysis of all data generated in QC rounds 1 to 6. Quantitative measurement of BCR-ABL1/ABL1 (B/A), and from QC3 onward also BCR-ABL1/GUS (B/G), was a common feature of all QC rounds with analyses for ABL1 or GUS as control genes (CG), respectively.
Paper tasks
To standardize interpretation of results, additional "paper tasks" were devised in which the laboratories were provided with virtual complex BCR-ABL1/ABL1 and BCR-ABL1/ GUS measurements and asked for data interpretation and reporting. All results were discussed in depth to clarify controversial and discordant results, providing a wellfounded basis for the development of guidelines.
Centralised sample preparation and quality assessment
Lyophilised cell dilutions ranging from 1% to 0.001% BCR-ABL1-positive SUP-B15 cells in BCR-ABL1-negative NALM6 cells, RNA and/or cDNA samples were prepared centrally and distributed on dry ice to the participating laboratories. Details of sample preparation and distribution are provided as supplemental data. (Suppl. Table 1 ).
Quality control of the samples prior to shipment was performed centrally by qRT-PCR using the standardized EAC protocols [25] . BCR-ABL1, ABL1, GUS were quantitated in either 3 or 2 independent runs, with one exception (QC8). Samples were scored as acceptable when all replicates were within 0.5 log. (Suppl. Table 2 ).
Plasmid standards
Centrally prepared plasmid standards were provided by Martin Müller (pME-3; Medical Faculty Mannheim of the University of Heidelberg, Germany and Nick Cross, Helen White (Wessex Regional Genetics Laboratory, Salisbury, UK). Both vectors contain a PCR-insert with e1a2 BCR-ABL1, ABL1 and GUS, and differ only in the vector itself and the size of the inserts. After large scale production, the plasmid DNA was quantified by spectrophotometry. The plasmid was then linearized and serial dilutions were prepared. They were stabilized in a water-based solution containing 20 ng/μl of msRNA (Roche Diagnostics, Mannheim, Germany). Six dilutions were prepared (2 to 2 × 10 5 copies). The corresponding standard curve typically generated a mean slope of −3.45 and an intercept of 41.57 for pME-3 (calculated from QC3, 4, 5, 6). A mean CT value of 27 was generated for 10 000 copies of ABL1 with a threshold set at 0.1.
Sample analysis by participating laboratories
Participants were asked to analyse the samples using the workflow given in Suppl. Table 1 . Using questionnaires that were repeatedly sent out throughout the study, laboratories also provided information on their in-house methods and standard approaches to expressing results and determining positivity and negativity.
Statistical methods
All the data were analyzed by the coordinating laboratory in Frankfurt. Results were presented during Euro-MRD meetings in a non-blinded manner. For Box-plot analysis, a 25 th -75 th percentile box with 10 th −90 th whiskers was used (median marked by line). Regression analysis was performed with the log B/A or B/G of the sample sets between individual participating laboratories and reference (log (median of B/A or B/G value)). Statistical analysis was performed using the GraphPad Prism™ software package version 6.02 (San Diego, USA).
Results
Trial participants and routine methodology
A total of 35 laboratories contributed, 8 from the EWALL, 22 from EuroMRD and 5 additional laboratories with high sample throughput and/or responsibility for CML validation within the EUTOS consortium. The routine methodologies for RNA extraction, cDNA synthesis and qRT-PCR are described under supplemental table 3.
Initial testing phase
Variability of RNA-Extraction
In the first QC, RNA extraction was performed from centrally prepared aliquots of cell dilutions lysed and homogenized in TRIzol ® reagent and shipped on dry ice. The amount of RNA extracted from identical aliquots by different laboratories using the same extraction method varied substantially, ranging from 0.66 μg to 49.1 μg (Suppl. Figure 3A) .
The ABL1 copy number following RNA extraction and cDNA preparation likewise showed substantial variability as displayed in the box plots in Supplemental Fig. 3B . Uniform use of TRIzol ® -based RNA extraction therefore did not improve inter-laboratory variability.
Assay sensitivity in relation to control gene
As a measure of assay sensitivity for the various dilutions of e1a2 BCR-ABL1 positive cells (total cells per sample: 5 × 10 6 ), the median number of ABL1 copies generated during the initial testing phase was 5.4 × 10 4 , (range 0-2.41 × 10 6 ) (n = 22 laboratories) (Suppl. Figure 3B ). Nine laboratories failed to reach the threshold of 10 4 ABL1 copies in at least one of seven samples. Overall assay sensitivity across laboratories was thus considered suboptimal, despite sufficient cell numbers available for extraction.
Exemplarily, for GUS as CG, the median copy number was 6.4 × 10 4 (2.13 × 10 4 -3.71 × 10 6 ) (QC4, using centrally prepared cDNA). With the exception of one outlier, no laboratory measured fewer than 10 4 GUS copies in any sample (Suppl. Figure 4B ). The median ABL1 amount also revealed sufficient assay sensitivity in all laboratories (QC4). (Suppl. Figure 4A )
Intra-and inter-laboratory variability was higher when cells instead of cDNA were used as starting material, corresponding to the fewer analytical steps prior to the qRT-PCR reaction. (Fig. 2 
, Suppl. Figures 1 and 2).
Concordance of BCR-ABL1 transcript levels between laboratories
As shown in Fig. 1 , the BCR-ABL1/ABL1 ratios varied. Across all QC rounds and all samples, the inter-laboratory variability of BCR-ABL1 transcripts levels correlated inversely with the number of transcripts analyzed ( Fig. 1 ). For example, in QC1, the range of B/A ratios in samples with median B/A ratios of 1.99 × 10 −1 , 4.41 × 10 −2 ; 2.53 × 10 −2 covered a range of 2.26 log, 1.82 log and 1.81 log, respectively. At these dilutions, 61/67 (91%), 62/67 (93%) and 56/67 (83%) of analyses measuring BCR-ABL1/ABL1 ratio were within 1 log of the median and there were no false negatives. (Fig. 1a) For the median B/A of 2.5 × 10 −3 , 40 out of 67 (60%) analysis were within 0.25 log, 52 of 67 (78%) analysis were within 0.5 log, 62 of 67 (93%) analyses were within 1 log above or below the median. The overall range of B/A ratios was substantially broader (0 to 0.03) with 2 of 22 laboratories measuring no BCR-ABL1 in this sample. (Fig. 1a ) Deviation from the median at the lowest BCR-ABL1 transcript numbers (sample 6 in Fig. 1a ; median 2.26 × 10 -5 ) was large, ranging from negative to 2.09 log above the median. In 21 of 67 analyses (31%) e1a2 BCR-ABL1 was negative in at least one replicate. 8/22 (36%) laboratories failed to measure this sample as positive.
The data obtained with GUS instead of ABL1 as CG were comparable ( Fig. 1c, d) . The substantially greater variability of B/A or B/G ratios and a higher proportion of negative results at low BCR-ABL1 transcript levels are attributable to low transcript numbers often being below the quantitative range of the qRT-PCR assay.
To determine linearity and sensitivity of the results from each participating laboratory, we performed a linear regression analysis in which we compared the log B/A ratios obtained by the reference (the median of B/A ratios) and participating laboratories. As an example, twenty of 22 (90.9%) local laboratories obtained linear results (R² > 0.98)
C BCR-ABL1/GUS (in-house QC4) D BCR-ABL1/GUS (in-house QC10)
A e1a2 BCR-ABL1/ABL1 (in-house QC1) B e1a2 BCR-ABL1/ABL1 (in-house QC10) Fig. 1 Inter-laboratory variability of e1a2 BCR-ABL1 transcript levels using ABL1 or GUS as CGs using in-house methods. BCR-ABL1 quantitation is represented by the ratio of BCR-ABL1 copy number and ABL1 copy number plotted on the y-axis (log-transformed). On the x-axis, the sample ID represents different dilutions of centrally prepared TRIzol®-stabilized cells (a), lyophilised cells (b, d) or cDNA (c) that were measured by the participating laboratories in QC rounds 1 and 10 for ABL1 and QC rounds 4 and 10 for GUS. In case of repeat analyses, all data sets are integrated. The median corresponds to the horizontal line, the box refers to the range defined by the 25th and 75th percentiles, the whiskers refer to the range defined by the 10-90 percentiles. Outliers are indicated by dots. Each datapoint represents the mean of triplicate analyses of each measurement performed by the participating centers when plotted on a log scale (QC1, Suppl. Figure 5A ). The non-linear fit of data from 2 laboratories suggested an unsatisfactory amplification efficiency of the respective PCR technique within the meaningful diagnostic range. Results with GUS as CG were similar (QC4, Suppl. Figure 5B ).
Impact of methodology on inter-laboratory variability
Poor reproducibility of BCR-ABL1 quantitation below quantitative range (Fig. 1 (Fig. 2, QC6 , sample 6). Thus, centralisation of cDNA synthesis did not significantly improve interlaboratory variability when transcript levels were below the quantitative range (10 copies). SuperScript and M-MLV, the principal enzymes used for cDNA synthesis, were comparable in terms of the B/A ratios ( Fig. 3a ) and the ABL1 amount (Suppl. Figure 6A) , irrespective of the BCR-ABL1 transcript level. Comparison of the cycler types revealed no difference with respect to either the B/A ratio (Fig. 3b ) or ABL1 amount (Suppl. Figure 6B ). Inter-laboratory variability decreased with the use of a centrally prepared plasmid standards (Fig. 4, Suppl. Figures 1 and 2, 7A and B and Supplemental data).
Sensitivity and specificity
The frequency of false-negative and false-positive results was analysed in all QC rounds by evaluating blinded negative and low-positive samples ( Table 1) . False-positive results were generated by 12% to 27% of laboratories in 6/ 10 QC rounds. No individual laboratory was disproportionally represented. The frequency of false-negative results differed by transcript level: at B/A ratios between 1 × 10 −4 and 5 × 10 −4 , any false negativity occurred in only 2/9 QC rounds, whereas false-negative results occurred in 6 of 6 QC rounds at B/A ratios below 10 −4 ( Table 1) . Fig. 2 Inter-laboratory variability of e1a2 BCR-ABL1 quantitation in relation to centrally vs. locally prepared cDNA as starting material prior to qRT-PCR. In QC6, a pool of centrally prepared RNA was separated into aliquots which were either sent out to the individual laboratories (n = 26) who then performed the cDNA synthesis followed by qRT-PCR, or were processed to cDNA, again pooled and then sent out by the central laboratory. With these samples, the participating laboratories performed only the quantitative PCR. The ratio is defined as the ratio between the copy numbers of BCR-ABL1 and ABL1 plotted on the y-axis (log-transformed). The median corresponds to the horizontal line, the box refers to the range defined by the 25 th and 75 th percentiles, the whiskers refer to the range defined by the 10-90 percentiles. Outliers are indicated by dots. Each datapoint represents the mean of triplicate analyses of each measurement performed by the participating centers A local cDNA synthesis and BCR-ABL1/ABL1 ratio, enzymes B local cDNA synthesis and BCR-ABL1/ABL1 ratio by cycler type Fig. 3 Inter-laboratory variability of e1a2 BCR-ABL1/ ABL1 quantitation in relation to the method of cDNA synthesis and cycler platform. Samples were supplied as centrally produced RNA or cDNA, and the participating laboratories were asked to perform either cDNA-synthesis and real-time PCR or real-time PCR alone (QC6, Sample 1 & 5). On the yaxis the BCR-ABL1/ABL1 ratio of all results coming from the individual labs are shown (logtransformed), the LAB ID is given on the x-axis. Each dot corresponds to the median of three replicates. a is a comparison of different cDNA enzymes using MMLV or Superscript. b is a comparison of different cycler platforms.Each datapoint represents the mean of triplicate analyses of each measurement performed by the participating centers A BCR-ABL1/ABL1 B BCR-ABL1/GUS Fig. 4 Inter-laboratory variability of e1a2 BCR-ABL1 transcript quantitation using identical plasmid standards. In QC10, samples with an intermediate (BCR-ABL1/ABL1 ratio 10 −3 ) e1a2 BCR-ABL1 transcript level were provided as cell pellets. Laboratories were asked to perform RNA extraction, followed by two rounds of cDNA synthesis and qRT-PCR performed on separate days. The e1a2 BCR-ABL1/ ABL1 ratios for these paired samples are depicted as a quadrat for the first and a triangle for the second cDNA synthesis for each individual laboratory, as indicated by the lab ID on the x-axis. a is a comparison for the BCR-ABL1/ABL1 results, b is the comparison for the BCR-ABL1/GUS results. On the right hand side of the two panels, the horizontal line represents the median of all measurements performed by all laboratories, the box refers to the range defined by the 25th and 75th percentiles, the whiskers refer to the range defined by the 10-90 percentiles. Outliers are indicated by dots. Each datapoint represents the mean of triplicate analyses of each measurement performed by the participating centers. The y-axis is scaled to cover 2 logs (log scale) 
Guidelines for interpretation
Definition of quantitative range and sensitivity
The paper tasks revealed that laboratories initially used different criteria for reporting qRT-PCR results, particularly with low-level positive samples, e.g. when single replicates were positive below 10 BCR-ABL1 copies. We therefore developed guidelines for data interpretation analogous to those described for qPCR of Ig/TCR rearrangements [17] ( Table 2 ).
The main difference between these guidelines is a more stringent definition for the slope (3.2-3.7) compared with the guidelines published for Ig/TCR quantitation (3.1-3.9). The BCR-ABL1 assay is a uniform assay and therefore likely to be equally efficient between different patients, whereas IG/TCR assays are patient-specific and therefore highly variable, which accounts for the higher variability in the efficacy of the PCR reaction and consequently in a wider range for the slope of the standard curve. Based on evaluation of commercial plasmid standard curves (n = 65, minor-BCR-ABL1 standards, QC 1-6), 50% of the slopes were between −3.46 and −3.386 and 61/65 (94%) were between −3.7 and −3.2, which therefore was chosen pragmatically as acceptable range. 154 data sets from in-house plasmid standard curves (QC 1-6) were evaluated for defining the acceptable Delta-CT: 2.6-4.0 (25th-75th percentile 2.882-3.633, range 1.4-6.4) ( Fig. 5 ).
Discussion
MRD is an independent prognostic factor for Ph + ALL and may be used as a trigger for therapeutic intervention [21-23, • If the Delta-CT of the replicates is ≤ 1.5
• If the mean CT value is less than or equal to the highest CT value of the quantitative range • MRD-positive samples outside the quantitative range: scored as positive, outside quantitative range. Optimal sample quality • ≥ 10.000 ABL1 copies
• The minimum ABL1 amount for calculating a ratio should be evaluated by further patient data.
Fig. 5
Ability of laboratories to detect BCR-ABL1 copies within the QR. An example representing one of 156 data sets showing the ability of participating laboratories to detect 10 to 100 BCR-ABL1 copies from the plasmid standard (using in-house plasmids) within the quantitative range defined in QC6. On the y-axis, the delta-CT between 10 and 100 copies is shown. The lab ID is given on the x-axis. On the right hand side, the median corresponds to the horizontal line, the box refers to the range defined by the 25th and 75th percentiles, the whiskers refer to the range defined by the minimum and maximum. Abbreviations: QR, quantitative range [36] [37] [38] [39] [40] [41] [42] but validity and comparability of MRD results obtained by BCR-ABL1 transcript analysis are uncertain given the lack of standardisation. Our initial comparison of laboratory procedures among participating laboratories revealed almost universal use of EAC primer/probe sets [16] , which were therefore accepted as existing standard. Otherwise, no two laboratories initially followed exactly the same protocols, prompting us to evaluate the impact of other workflow conditions in successive QC rounds. Data obtained during the consecutive QA rounds showed that assay sensitivity was particularly related to an individual laboratory´s experience with a qRT-PCR protocol rather than to a specific method. Likewise, BCR-ABL1 and control gene copy numbers were not systematically affected by the choice of enzymes or type of thermocycler. Successive QC rounds showed that adopting the EAC primer/probe sets, common plasmid standards, the use of defined technical criteria for quality assurance, and common definitions of molecular response and data interpretation, allowed accurate measurement of MRD in Ph + ALL across numerous laboratories. There was no apparent benefit in more comprehensive standardisation of other components of the laboratory workflow. However, use of a secondary reference panel for BCR-ABL1 quantification, as recently published for MRD analysis in CML [43] may further improve the accuracy and consistency of MRD results across laboratories.
The choice of control gene presently remains controversial. ABL1 is used most commonly and yielded results similar to those obtained with GUS, if MRD levels were low. However, at higher BCR-ABL1 levels, such as at diagnosis, the use of ABL as control gene will underestimate BCR-ABL1 levels relative to control gene levels (since the EAC ABL1 PCR will also detect BCR-ABL1 transcripts, control gene levels will be over-estimated at high MRD levels). Since BCR-ABL1 MRD levels in ALL are frequently expressed relative to levels at diagnosis, the use of GUS as control gene seems more appropriate and is therefore strongly recommended.
Throughout the QC rounds, the distinction between detectable and undetectable disease was a critical issue at ≤10 BCR-ABL1 copies. It became apparent that this challenge was initially compounded by differences in the way individual laboratories interpreted data. By conducting paper tasks, it was demonstrated that variable approaches to interpretation of the same data sets led to substantial discrepancies in the reporting of results, comparable to our experiences for antigen receptor gene rearrangements-based MRD analysis [17] . This problem was largely alleviated by formulating guidelines for data interpretation and reporting that were adhered to by all consortium members, and were reinforced by regular discussions during meetings of the consortium. Despite the introduced guidelines, classification of negative samples as questionably positive still occurred in all QC rounds; this was however not attributable to specific sites, indicating there was no systematic analytical flaw affecting individual laboratories.
Although transcript values fell within a half log range in 60% of replicate analyses and within 1 log in 78% of replicate analyses (QC1) at a transcript level of 10 −3 , the total range of values spanned a range of up to 3 log. Variability was even more pronounced at transcript levels of ≤10 −4 and coincided with a clinically relevant rate of falsepositive and false-negative results. As expected from comprehensive standardisation efforts conducted in the CML field, use of common plasmid standards instead of cell lines or e1a2 oligonucleotides in the workflow of all laboratories had a profoundly positive impact on interlaboratory variability. Results obtained with commercially available, centrally prepared or in-house plasmids were comparable. The importance of plasmid calibrators to accurately determine the number of BCR-ABL1 and control gene transcripts in CML has led to the development of an internationally accepted certified plasmid reference material for BCR-ABL1 in CML [44] . A similar approach would be desirable for e1a2 BCR-ABL1 to ensure international comparability of MRD results for Ph + ALL. Meanwhile, laboratories performing MRD testing for multicentre clinical trials of Ph + ALL should use identical, centrally prepared or commercial plasmid reference material.
In CML, a test-specific IS conversion factor to enable comparability of BCR-ABL1 assays was developed and successfully implemented in a large number of laboratories, but is expensive and time consuming [45, 46] . Our consensus to not implement such a conversion factor for MRD analysis in Ph + ALL reflects reliance on a far smaller number of laboratories that also usually function as national or cooperative group reference laboratories. Moreover, patients with Ph + ALL are treated predominantly within national cooperative group trials rather than in a community setting. This different environment with a limited number of laboratories facilitates regular participation in QC rounds that are necessary to reinforce adherence to agreed guidelines, facilitate data consistency and ensure comparability of MRD results, as shown previously for the optimization of MRD analysis based on detection of Ig/TCR rearrangements [14] . The EURO-MRD now conducts QC rounds for e1a2 BCR-ABL1 analysis twice per year.
As clinical management of Ph + ALL is far more heterogeneous than that of CML, depend on diverse treatment protocols and the clinical context, e.g. adult or pediatric or pre-versus post-transplant settings, it was not our aim to define specific clinical recommendations for MRD testing in Ph + ALL. However, our guidelines listed in Table 2 together with the consensus terminology of the second international symposium on MRD assessment [15] provide a technical basis for uniform and correct interpretation of MRD results. Nevertheless, a number of clinical recommendations can be made based on discussions within our consortium and published data.
First, different thresholds and time points have been used by different national cooperative study groups to define molecular remission for Ph + ALL. Similarly, timing of MRD testing is important but it´s predictive value depends considerably on the specific treatment regimen employed, although several underlying principles apply. In general, a good early response after induction therapy is more informative of a favourable outcome, whereas persisting levels after consolidation are indicative of a poor prognosis [47] . During the early treatment period, MRD testing should be frequent, e.g. after every other cycle of chemotherapy, with more frequent analyses in case of high or rising BCR-ABL1 transcript levels. Testing at a single time-point may be informative but serial testing is recommended as it provides important information on disease dynamics [48] . In patients undergoing SCT, MRD should be determined within a short time window prior to start of conditioning, as the MRD level before SCT may be predictive of outcome [49, 50] . The first post-transplant MRD test should be performed approximately 4 weeks after SCT and be followed by more frequent analyses than is customary in CML. The EBMT recommends serial assessment of BM every 6 weeks and PB every 3 weeks, based on a prospective randomized trial investigating two schedules of TKI maintenance after SCT [37] . It should be stressed that our analyses was not designed to assign clinical relevance to a specific MRD level but to provide a framework for standardised MRD analysis, allowing comparison of MRD data from multiple future studies and thereby facilitating identification of most informative time points and cut-off levels for Ph + ALL patients.
Second, the material used for MRD analysis clearly impacts on results. As for other BCP-ALL, and in contrast to CML, bone marrow is the preferred source for quantification of MRD in Ph + ALL, since MRD levels typically are 1-3 log higher than in peripheral blood, without good correlation between BM and PB [51] .
In occasional patients it may be difficult to obtain good BM aspirates, particularly after SCT with TBI-based conditioning, in which case MRD sensitivity may be higher in PB. A large proportion of BM tests carried out prior to extramedullary relapse may be negative; [52] [53] [54] definite MRD positivity in PB in conjunction with negative results in bone marrow may be associated with invasion of extramedullary sites [55] . It is therefore advisable to send BM and PB samples in parallel.
Third, a good quality bone marrow sample, i.e. the first aspirate, should be used for MRD analysis. The aspirate should be collected after hematopoietic recovery following chemotherapy to ensure sufficient cellularity and assay sensitivity. Prompt delivery to the laboratory conducting the MRD analysis is critical, shipment delays over 48 h need to be avoided since this may impact transcript levels [56] .
The upcoming QC and standardisation efforts will be extended to include quantification of Major-BCR-ABL1 transcripts, as this breakpoint is present in approximately 30% of patients with Ph + ALL. Reagents such as secondary BCR-ABL1 reference panels developed by the CML field should prove instrumental in more rapidly reaching consensus on quantification of this second largest type of BCR-ABL1 transcripts.
In conclusion, our guidelines provide a robust framework for precise and reproducible qRT-PCR based analyses of e1a2 BCR-ABL1 transcripts and will facilitate valid comparison of MRD results between clinical trials for Ph + ALL. Adhering to this standard set of recommendations will help answering clinically unresolved questions about the prognostic and predictive value of specific BCR-ABL1 thresholds and dynamics in distinct therapeutic settings, and help resolve a number of clinical management issues that depend on accurate quantification of BCR-ABL1 transcripts.
